• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases.巴西的黄热病疫苗接种：青少年自身免疫性风湿病的短期安全性和免疫原性
Vaccine X. 2021 Dec 10;10:100131. doi: 10.1016/j.jvacx.2021.100131. eCollection 2022 Apr.
2
Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.原发性小剂量黄热病疫苗在自身免疫性风湿性疾病中的免疫原性和安全性
PLoS Negl Trop Dis. 2021 Nov 29;15(11):e0010002. doi: 10.1371/journal.pntd.0010002. eCollection 2021 Nov.
3
Immunogenicity and safety of routine vaccines in children and adolescents with rheumatic diseases on immunosuppressive treatment - a systematic review.免疫原性和安全性常规疫苗在儿童和青少年与风湿性疾病在免疫抑制治疗-系统评价。
Eur J Pediatr. 2022 Apr;181(4):1329-1362. doi: 10.1007/s00431-021-04283-w. Epub 2021 Dec 22.
4
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.计划接种黄热病疫苗对自身免疫性疾病患者是安全且具有免疫原性的：一项前瞻性非干预性研究。
Front Immunol. 2020 Jul 17;11:1382. doi: 10.3389/fimmu.2020.01382. eCollection 2020.
5
Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1.
J Travel Med. 2020 Sep 26;27(6). doi: 10.1093/jtm/taaa126.
6
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.计划原发性 17DD 黄热病疫苗接种后，血清生物标志物谱协调自身免疫性疾病患者的血清转化状态。
Sci Rep. 2021 May 17;11(1):10431. doi: 10.1038/s41598-021-89770-8.
7
Safety of the yellow fever vaccine in people living with HIV: a longitudinal study exploring post-vaccination viremia and hematological and liver kinetics.HIV 感染者接种黄热病疫苗的安全性：一项探索疫苗接种后病毒血症以及血液学和肝脏动力学的纵向研究。
Braz J Infect Dis. 2024 Jan-Feb;28(1):103719. doi: 10.1016/j.bjid.2024.103719. Epub 2024 Feb 7.
8
Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.17DD 黄热病疫苗分剂给药在男性和女性中的安全性概况：来自刚果民主共和国金沙萨社区药物警戒的经验。
Vaccine. 2018 Oct 1;36(41):6170-6182. doi: 10.1016/j.vaccine.2018.08.052. Epub 2018 Sep 3.
9
Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.黄热病疫苗与麻疹、腮腺炎和风疹联合疫苗免疫应答的相互干扰。
Vaccine. 2011 Aug 26;29(37):6327-34. doi: 10.1016/j.vaccine.2011.05.019. Epub 2011 Jun 2.
10
Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease.糖皮质激素：降低幼年特发性关节炎患者对 2009 年甲型 H1N1 流感疫苗免疫原性的主要因素。
J Rheumatol. 2012 Jan;39(1):167-73. doi: 10.3899/jrheum.110721. Epub 2011 Nov 15.

引用本文的文献

1
Yellow Fever Vaccine-Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil.巴西圣保罗州黄热病疫苗相关内脏疾病在兄弟姐妹间的传播
Emerg Infect Dis. 2023 Mar;29(3):493-500. doi: 10.3201/eid2903.220989.
2
Vaccinology in pediatric rheumatology: Past, present and future.儿童风湿病中的疫苗学：过去、现在与未来
Front Pediatr. 2023 Jan 10;10:1098332. doi: 10.3389/fped.2022.1098332. eCollection 2022.

本文引用的文献

1
Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection.免疫抑制治疗的风湿性疾病患儿使用减毒活疫苗（MMR/V）加强疫苗是安全的：多中心回顾性数据收集。
Vaccine. 2020 Feb 24;38(9):2198-2201. doi: 10.1016/j.vaccine.2020.01.037. Epub 2020 Jan 24.
2
Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.小剂量黄热病疫苗接种后的长期保护作用：一项随机、对照、非劣效性试验的随访研究。
Ann Intern Med. 2018 Dec 4;169(11):761-765. doi: 10.7326/M18-1529. Epub 2018 Nov 27.
3
The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey.使用白细胞介素-1或白细胞介素-6阻断剂的患者中减毒活疫苗的安全性：一项国际调查。
Pediatr Rheumatol Online J. 2018 Mar 21;16(1):19. doi: 10.1186/s12969-018-0235-z.
4
Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.黄热病疫情期间亚单位疫苗的免疫原性 - 最终报告。
N Engl J Med. 2019 Aug 1;381(5):444-454. doi: 10.1056/NEJMoa1710430. Epub 2018 Feb 14.
5
Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics.免疫抑制或免疫调节治疗下活疫苗的安全性：瑞士三家旅行诊所的回顾性研究。
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tax082.
6
T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models.针对黄热病病毒的T细胞介导免疫及有用的动物模型
Viruses. 2017 Apr 11;9(4):77. doi: 10.3390/v9040077.
7
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review.接种疫苗后出现的不良事件——中性粒细胞减少症：健康成年人随机临床试验结果及系统评价
PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016.
8
Type I interferons in viral control and immune regulation.I型干扰素在病毒控制和免疫调节中的作用
Curr Opin Virol. 2016 Feb;16:31-40. doi: 10.1016/j.coviro.2016.01.001. Epub 2016 Jan 24.
9
Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.在接受或未接受抗TNF治疗的传统改善病情抗风湿药治疗的幼年特发性关节炎患者中，接种23价肺炎球菌多糖疫苗后的短期和长期免疫原性及安全性。
Vaccine. 2015 Jan 29;33(5):604-9. doi: 10.1016/j.vaccine.2014.12.030. Epub 2014 Dec 29.
10
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.接受免疫调节剂或免疫抑制剂治疗的风湿性疾病患者在无意中再次接种黄热病疫苗后发生血清转化。
Arthritis Rheumatol. 2015 Feb;67(2):582-3. doi: 10.1002/art.38960.

巴西的黄热病疫苗接种：青少年自身免疫性风湿病的短期安全性和免疫原性

Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases.

作者信息

Emi Aikawa Nádia, Andrade Balbi Verena, Borba Eduardo Ferreira, Coracini Tonacio Adriana, Maluf Elias Sallum Adriana, Maria Arruda Campos Lucia, Tomie Kozu Kátia, Borges Vendramini Margarete, Fontoura Nicole, de Souza Azevedo Adriana, Dias Schwarcz Waleska, Marli Christovam Sartori Ana, Antonangelo Leila, Artur Silva Clovis, Bonfá Eloisa

机构信息

Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, Brazil.

Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, Brazil.

出版信息

Vaccine X. 2021 Dec 10;10:100131. doi: 10.1016/j.jvacx.2021.100131. eCollection 2022 Apr.

DOI:10.1016/j.jvacx.2021.100131
PMID:34977552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8686021/
Abstract

Yellow fever vaccine (YFV) is a live attenuated vaccine usually contraindicated for juvenile autoimmune rheumatic disease (JARD) patients. During the recent epidemic in Sao Paulo-Brazil, YFV was indicated for patients under low immunosuppression. Thirty JARD patients with inactive diseases undergoing low immunosuppression and 30 healthy controls (HC) were vaccinated with a fractional dose 17DD YFV (∼5495 IU) and evaluated 30 days later. JARD patients and controls had comparable median age (12.4 vs. 12 years, p = 0.250). Disease parameters remained stable 30 days after 17DD YFV (p > 0.05) and only mild adverse events were reported in both groups (p > 0.05). JARD and HC had similar seroprotection [93% vs. 100%;p = 0.49], seroconversion rates [96% vs. 100%;p = 0.489], and GMT [1249 vs.1293;p = 0.821]. Both groups had similar white-blood-cells kinetics with transient decreases in lymphocytes at D5 and neutrophils at D10, followed by full recovery at D30 (P < 0.05). In conclusion, 17DD YFV was safe and immunogenic in JARD. This study may contribute to recommendations for patients living/travelling to endemic areas.

摘要

黄热病疫苗（YFV）是一种减毒活疫苗，通常对青少年自身免疫性风湿病（JARD）患者禁用。在巴西圣保罗最近的疫情期间，YFV被用于低免疫抑制的患者。30例处于疾病缓解期且接受低免疫抑制治疗的JARD患者和30名健康对照（HC）接种了17DD YFV的分剂量（约5495国际单位），并在30天后进行评估。JARD患者和对照组的年龄中位数相当（12.4岁对12岁，p = 0.250）。17DD YFV接种30天后疾病参数保持稳定（p>0.05），两组均仅报告了轻微不良事件（p>0.05）。JARD组和HC组的血清保护率[93%对100%；p = 0.49]、血清转化率[96%对100%；p = 0.489]和几何平均滴度[1249对1293；p = 0.821]相似。两组的白细胞动力学相似，在第5天淋巴细胞短暂减少，第10天中性粒细胞短暂减少，随后在第30天完全恢复（P<0.05）。总之，17DD YFV在JARD患者中是安全且具有免疫原性的。本研究可能有助于为生活在/前往疫区的患者提供建议。